Patents by Inventor Yoshimasa Takahashi
Yoshimasa Takahashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945336Abstract: An information creation apparatus includes a processor configured to, in a case where priorities of power supply are set to power supply targets, set upper limits of power storage remaining amounts of the power supply targets such that the upper limit of the power storage remaining amount of a power supply target with a lower priority is set to a value larger than a reference value.Type: GrantFiled: July 14, 2021Date of Patent: April 2, 2024Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Yoshimasa Watanabe, Kizuku Yamada, Masaki Ito, Sakiko Yoshida, Yuki Takahashi, Tomonori Imamura
-
Publication number: 20230406910Abstract: Provided is a method for producing an influenza HA split vaccine which produces an antibody that binds to a HA stem region of influenza, the HA stem region being less likely to cause antigenic variation, An influenza HA split vaccine is subjected to an acidic treatment. Through the acidic treatment, an influenza HA split vaccine which produces an antibody that binds to a LAH of the HA stem region is obtained. This influenza HA split vaccine has an excellent protective ability against infection of other influenza viruses of different antigenicity.Type: ApplicationFiled: June 27, 2023Publication date: December 21, 2023Inventors: Yoshimasa Takahashi, Yu Adachi, Manabu Ato
-
Publication number: 20230348573Abstract: An antibody against spike protein of SARS-CoV-2 is provided, the antibody having a specific heavy chain variable region and a specific light chain variable region, or a fragment of the antibody, the antibody or fragment thereof inhibiting the binding between the spike protein of SARS-CoV-2 and ACE2, the antibody or fragment thereof inhibiting SARS-CoV-2 infection; and a pharmaceutical composition including the antibody or fragment thereof and a pharmaceutically acceptable carrier, the pharmaceutical composition including two or more kinds of the antibody or fragment thereof.Type: ApplicationFiled: September 24, 2021Publication date: November 2, 2023Applicants: KEIO UNIVERSITY, JAPAN as represented by DIRECTOR GENERAL of NATIONAL INSTITUTE OF INFECTIOUS DISEASES, RIKEN, SHIGA UNIVERSITY OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYOInventors: Masaru TAKESHITA, Tsutomu TAKEUCHI, Katsuya SUZUKI, Hideyuki SAYA, Yoshimasa TAKAHASHI, Saya MORIYAMA, Hidehiro FUKUYAMA, Chieko OKAMURA, Mikako SHIROUZU, Takehisa MATSUMOTO, Katsuhiko KAMADA, Yasushi ITOH, Hirohito ISHIGAKI, Misako NAKAYAMA, Yoshinori KITAGAWA, Yoshihiro KAWAOKA
-
Patent number: 11740688Abstract: A virtual space experience system capable of preventing unintentional contact between players without inhibiting a sense of immersion is provided. A virtual space image determination unit 35 of a VR system S causes an image of a virtual space to be perceived by a second player to include an image in which a first avatar corresponding to a first player moves so as to generate a gap in a correspondence relationship between coordinates of the first player and coordinates of the first avatar when a trigger event is recognized, and causes the image of the virtual space to be perceived by the second player to include an image of a second avatar corresponding to the second player and a third avatar corresponding to the first player after the recognition. An avatar coordinate determination unit 34 determines coordinates of the third avatar based on the coordinates of the first player.Type: GrantFiled: November 13, 2019Date of Patent: August 29, 2023Assignee: Abal Inc.Inventors: Shota Suzuki, Tsuyoshi Nomura, Yoshikatsu Kanemaru, Yoshiya Okoyama, Yoshimasa Takahashi
-
Patent number: 11732031Abstract: Provided is a method for producing an influenza HA split vaccine which produces an antibody that binds to a HA stem region of influenza, the HA stem region being less likely to cause antigenic variation, An influenza HA split vaccine is subjected to an acidic treatment. Through the acidic treatment, an influenza HA split vaccine which produces an antibody that binds to a LAH of the HA stem region is obtained. This influenza HA split vaccine has an excellent protective ability against infection of other influenza viruses of different antigenicity.Type: GrantFiled: March 4, 2019Date of Patent: August 22, 2023Assignee: JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious DiseasesInventors: Yoshimasa Takahashi, Yu Adachi, Manabu Ato
-
Publication number: 20230086835Abstract: Provided is a flavivirus cross neutralizing antibody which has an excellent ability to control infection with suppressed ADE. This is a flavivirus cross neutralizing antibody that specifically binds to domains of E protein of flavivirus and thereby has an ability to control infection with at least two viruses included in the flavivirus. The domains of E protein include a plurality of domains including domain III. The flavivirus includes, for example, Zika virus, dengue virus types 1-4, and Japanese encephalitis virus.Type: ApplicationFiled: February 4, 2021Publication date: March 23, 2023Applicant: Japan As Represented By Director General of National Institute of Infectious DiseasesInventors: Yoshimasa TAKAHASHI, Arnone NITHICHANON, Takayuki MATSUMURA, Ryosuke SUZUKI, Chang-Kweng LIM, Ganjana LERTMEMONGKOLCHAI
-
Publication number: 20220404899Abstract: A virtual space experience system capable of preventing unintentional contact between players without inhibiting a sense of immersion is provided. A virtual space image determination unit 35 of a VR system S causes an image of a virtual space to be perceived by a second player to include an image in which a first avatar corresponding to a first player moves so as to generate a gap in a correspondence relationship between coordinates of the first player and coordinates of the first avatar when a trigger event is recognized, and causes the image of the virtual space to be perceived by the second player to include an image of a second avatar corresponding to the second player and a third avatar corresponding to the first player after the recognition. An avatar coordinate determination unit 34 determines coordinates of the third avatar based on the coordinates of the first player.Type: ApplicationFiled: November 13, 2019Publication date: December 22, 2022Inventors: Shota SUZUKI, Tsuyoshi NOMURA, Yoshikatsu KANEMARU, Yoshiya OKOYAMA, Yoshimasa TAKAHASHI
-
Patent number: 11517616Abstract: The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L1-Xn—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].Type: GrantFiled: October 19, 2017Date of Patent: December 6, 2022Assignees: Denka Company Limited, TOKYO INSTITUTE OF TECHNOLOGY, THE KITASATO INSTITUTE, DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASESInventors: Takafumi Ueno, Kengo Yoshikawa, Megumi Mano, Kazuhiko Katayama, Motohiro Miki, Reiko Todaka, Yoshimasa Takahashi, Taishi Onodera
-
Patent number: 11505216Abstract: Provided is a transfer cart that that has a simple structure, facilitates operation in front and back spaces of a moving direction, and does not take up a redundant transfer space in a locations where operation is not performed. The transfer cart includes a running frame, a main carrier capable of carrying thereon an object to be transferred, and moving-direction operation decks disposed at front and back of the moving direction on the main carrier and running frame. The moving-direction operation decks are configured to change angle with the main carrier in accordance with the radius of curvature of a track, and configured to have a variable height mechanism to be able to change height thereof in the up and down direction.Type: GrantFiled: March 16, 2021Date of Patent: November 22, 2022Assignee: TSUBAKIMOTO CHAIN CO.Inventors: Motoshi Hamada, Daiki Kondo, Atsushi Nakagami, Yoshimasa Takahashi
-
Publication number: 20220152191Abstract: Provided is a method for producing an influenza HA split vaccine which produces an antibody that binds to an HA stem region of influenza, the HA stem region being less likely to cause antigenic variation, An influenza HA split vaccine is subjected to an acidic treatment. Through the acidic treatment, an influenza HA split vaccine which produces an antibody that binds to an LAH of the HA stem region is obtained. This influenza HA split vaccine has an excellent ability against infection of other influenza viruses of different antigenicity.Type: ApplicationFiled: March 3, 2020Publication date: May 19, 2022Inventors: Yoshimasa Takahashi, Yu Adachi, Manabu Ato
-
Publication number: 20210353737Abstract: The present invention provides a composition comprising a universal influenza vaccine antigen and a vaccine adjuvant.Type: ApplicationFiled: July 22, 2019Publication date: November 18, 2021Inventors: Yoshimasa Takahashi, Yu Adachi, Manabu Ato, Akihisa Fukushima
-
Publication number: 20210299240Abstract: The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L1-Xn—Y (1) [wherein W represents an amino acid sequence of P domain of the capsid protein of norovirus as an immunogen; L1 represents a first linker sequence having 0 to 100 amino acids; X represents an amino acid sequence represented by SEQ ID NO: 1; Y represents an amino acid sequence of a cell introduction domain; n is an integer of 1 to 3].Type: ApplicationFiled: October 19, 2017Publication date: September 30, 2021Applicants: DENKA COMPANY LIMITED, TOKYO INSTITUTE OF TECHNOLOGY, THE KITASATO INSTITUTE, JAPAN AS REPRESENTED BY DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASESInventors: Takafumi UENO, Kengo YOSHIKAWA, Megumi MANO, Kazuhiko KATAYAMA, Motohiro MIKI, Reiko TODAKA, Yoshimasa TAKAHASHI, Taishi ONODERA
-
Publication number: 20210291879Abstract: Provided is a transfer cart that that has a simple structure, facilitates operation in front and back spaces of a moving direction, and does not take up a redundant transfer space in a locations where operation is not performed. The transfer cart includes a running frame, a main carrier capable of carrying thereon an object to be transferred, and moving-direction operation decks disposed at front and back of the moving direction on the main carrier and running frame. The moving-direction operation decks are configured to change angle with the main carrier in accordance with the radius of curvature of a track, and configured to have a variable height mechanism to be able to change height thereof in the up and down direction.Type: ApplicationFiled: March 16, 2021Publication date: September 23, 2021Applicant: TSUBAKIMOTO CHAIN CO.Inventors: Motoshi Hamada, Daiki Kondo, Atsushi Nakagami, Yoshimasa Takahashi
-
Publication number: 20190345231Abstract: Provided is a method for producing an influenza HA split vaccine which produces an antibody that binds to a HA stem region of influenza, the HA stem region being less likely to cause antigenic variation, An influenza HA split vaccine is subjected to an acidic treatment. Through the acidic treatment, an influenza HA split vaccine which produces an antibody that binds to a LAH of the HA stem region is obtained. This influenza HA split vaccine has an excellent protective ability against infection of other influenza viruses of different antigenicity.Type: ApplicationFiled: March 4, 2019Publication date: November 14, 2019Inventors: Yoshimasa Takahashi, Yu Adachi, Manabu Ato
-
Patent number: 10301300Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: May 1, 2018Date of Patent: May 28, 2019Assignee: TEIJIN LIMITEDInventors: Takashi Shirakura, Yoshimasa Takahashi, Asahi Kawana, Chikashi Kanazawa
-
Publication number: 20180244665Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: May 1, 2018Publication date: August 30, 2018Applicant: Teijin Pharma LimitedInventors: Takashi SHIRAKURA, Yoshimasa TAKAHASHI, Asahi KAWANA, Chikashi KANAZAWA
-
Publication number: 20180179256Abstract: The present invention is directed to a sequence modification of the H7 hemagglutinin glycoprotein of the Influenza A/Shanghai/2/2013 H7 sequence together with vaccines derived therefrom. In addition, the invention further comprises method for improving the efficacy of vaccine antigens by modifying T cell epitopes.Type: ApplicationFiled: April 15, 2016Publication date: June 28, 2018Applicants: EpiVax, Inc., National Institute of Infectious DiseasesInventors: Anne S De Groot, William D Martin, Yoshimasa Takahashi, Manabu Ato
-
Patent number: 9856237Abstract: Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, Lesch-Nyhan syndrome, and the like.Type: GrantFiled: May 12, 2015Date of Patent: January 2, 2018Assignee: Teijin Pharma LimitedInventors: Akinobu Maruyama, Susumu Takeuchi, Yoshimasa Takahashi
-
Publication number: 20170217948Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: July 29, 2015Publication date: August 3, 2017Applicant: Teijin Pharma LimitedInventors: Takashi SHIRAKURA, Yoshimasa TAKAHASHI, Asahi KAWANA, Chikashi KANAZAWA
-
Publication number: 20170190694Abstract: Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with URAT1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and Lesch-Nyhan syndrome.Type: ApplicationFiled: March 22, 2017Publication date: July 6, 2017Applicant: Teijin Pharma LimitedInventors: Akinobu MARUYAMA, Hirofumi KAMADA, Mika FUJINUMA, Susumu TAKEUCHI, Hiroshi SAITOH, Yoshimasa TAKAHASHI